Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
Identifieur interne : 000F48 ( PubMed/Checkpoint ); précédent : 000F47; suivant : 000F49Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
Auteurs : Isabelle Boileau [Canada] ; Pablo Rusjan ; Sylvain Houle ; Diana Wilkins ; Junchao Tong ; Peter Selby ; Mark Guttman ; Jean A. Saint-Cyr ; Alan A. Wilson ; Stephen J. KishSource :
- The Journal of neuroscience : the official journal of the Society for Neuroscience [ 1529-2401 ] ; 2008.
English descriptors
- KwdEn :
- Adult, Analysis of Variance, Brain Mapping, Central Nervous System Stimulants (adverse effects), Corpus Striatum (diagnostic imaging), Corpus Striatum (pathology), Female, Humans, Magnetic Resonance Imaging (methods), Male, Methamphetamine (adverse effects), Middle Aged, Neurologic Examination (methods), Neuropsychological Tests, Parkinson Disease (diagnostic imaging), Positron-Emission Tomography, Radiopharmaceuticals (metabolism), Substance Withdrawal Syndrome (diagnostic imaging), Substance Withdrawal Syndrome (metabolism), Substance Withdrawal Syndrome (pathology), Substance Withdrawal Syndrome (physiopathology), Tetrabenazine (analogs & derivatives), Tetrabenazine (metabolism), Time Factors, Vesicular Monoamine Transport Proteins (metabolism).
- MESH :
- chemical , adverse effects : Central Nervous System Stimulants, Methamphetamine.
- chemical , analogs & derivatives : Tetrabenazine.
- diagnostic imaging : Corpus Striatum, Parkinson Disease, Substance Withdrawal Syndrome.
- chemical , metabolism : Radiopharmaceuticals, Substance Withdrawal Syndrome, Tetrabenazine, Vesicular Monoamine Transport Proteins.
- methods : Magnetic Resonance Imaging, Neurologic Examination.
- pathology : Corpus Striatum, Substance Withdrawal Syndrome.
- physiopathology : Substance Withdrawal Syndrome.
- Adult, Analysis of Variance, Brain Mapping, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Positron-Emission Tomography, Time Factors.
Abstract
Animal data indicate that methamphetamine can damage striatal dopamine terminals. Efforts to document dopamine neuron damage in living brain of methamphetamine users have focused on the binding of [(11)C]dihydrotetrabenazine (DTBZ), a vesicular monoamine transporter (VMAT2) positron emission tomography (PET) radioligand, as a stable dopamine neuron biomarker. Previous PET data report a slight decrease in striatal [(11)C]DTBZ binding in human methamphetamine users after prolonged (mean, 3 years) abstinence, suggesting that the reduction would likely be substantial in early abstinence. We measured striatal VMAT2 binding in 16 recently withdrawn (mean, 19 d; range, 1-90 d) methamphetamine users and in 14 healthy matched-control subjects during a PET scan with (+)[(11)C]DTBZ. Unexpectedly, striatal (+)[(11)C]DTBZ binding was increased in methamphetamine users relative to controls (+22%, caudate; +12%, putamen; +11%, ventral striatum). Increased (+)[(11)C]DTBZ binding in caudate was most marked in methamphetamine users abstinent for 1-3 d (+41%), relative to the 7-21 d (+15%) and >21 d (+9%) groups. Above-normal VMAT2 binding in some drug users suggests that any toxic effect of methamphetamine on dopamine neurons might be masked by an increased (+)[(11)C]DTBZ binding and that VMAT2 radioligand binding might not be, as is generally assumed, a "stable" index of dopamine neuron integrity in vivo. One potential explanation for increased (+)[(11)C]DTBZ binding is that VMAT2 binding is sensitive to changes in vesicular dopamine storage levels, presumably low in drug users. If correct, (+)[(11)C]DTBZ might be a useful imaging probe to correlate changes in brain dopamine stores and behavior in users of methamphetamine.
DOI: 10.1523/JNEUROSCI.3008-08.2008
PubMed: 18815269
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:18815269Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?</title><author><name sortKey="Boileau, Isabelle" sort="Boileau, Isabelle" uniqKey="Boileau I" first="Isabelle" last="Boileau">Isabelle Boileau</name><affiliation wicri:level="4"><nlm:affiliation>Human Neurochemical Pathology Laboratory, University of Toronto, Toronto, Ontario, Canada. isabelle_boileau@camh.net</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Human Neurochemical Pathology Laboratory, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Rusjan, Pablo" sort="Rusjan, Pablo" uniqKey="Rusjan P" first="Pablo" last="Rusjan">Pablo Rusjan</name></author><author><name sortKey="Houle, Sylvain" sort="Houle, Sylvain" uniqKey="Houle S" first="Sylvain" last="Houle">Sylvain Houle</name></author><author><name sortKey="Wilkins, Diana" sort="Wilkins, Diana" uniqKey="Wilkins D" first="Diana" last="Wilkins">Diana Wilkins</name></author><author><name sortKey="Tong, Junchao" sort="Tong, Junchao" uniqKey="Tong J" first="Junchao" last="Tong">Junchao Tong</name></author><author><name sortKey="Selby, Peter" sort="Selby, Peter" uniqKey="Selby P" first="Peter" last="Selby">Peter Selby</name></author><author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name></author><author><name sortKey="Saint Cyr, Jean A" sort="Saint Cyr, Jean A" uniqKey="Saint Cyr J" first="Jean A" last="Saint-Cyr">Jean A. Saint-Cyr</name></author><author><name sortKey="Wilson, Alan A" sort="Wilson, Alan A" uniqKey="Wilson A" first="Alan A" last="Wilson">Alan A. Wilson</name></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J" last="Kish">Stephen J. Kish</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18815269</idno><idno type="pmid">18815269</idno><idno type="doi">10.1523/JNEUROSCI.3008-08.2008</idno><idno type="wicri:Area/PubMed/Corpus">000F47</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F47</idno><idno type="wicri:Area/PubMed/Curation">000F47</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F47</idno><idno type="wicri:Area/PubMed/Checkpoint">000F47</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?</title><author><name sortKey="Boileau, Isabelle" sort="Boileau, Isabelle" uniqKey="Boileau I" first="Isabelle" last="Boileau">Isabelle Boileau</name><affiliation wicri:level="4"><nlm:affiliation>Human Neurochemical Pathology Laboratory, University of Toronto, Toronto, Ontario, Canada. isabelle_boileau@camh.net</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Human Neurochemical Pathology Laboratory, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Rusjan, Pablo" sort="Rusjan, Pablo" uniqKey="Rusjan P" first="Pablo" last="Rusjan">Pablo Rusjan</name></author><author><name sortKey="Houle, Sylvain" sort="Houle, Sylvain" uniqKey="Houle S" first="Sylvain" last="Houle">Sylvain Houle</name></author><author><name sortKey="Wilkins, Diana" sort="Wilkins, Diana" uniqKey="Wilkins D" first="Diana" last="Wilkins">Diana Wilkins</name></author><author><name sortKey="Tong, Junchao" sort="Tong, Junchao" uniqKey="Tong J" first="Junchao" last="Tong">Junchao Tong</name></author><author><name sortKey="Selby, Peter" sort="Selby, Peter" uniqKey="Selby P" first="Peter" last="Selby">Peter Selby</name></author><author><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name></author><author><name sortKey="Saint Cyr, Jean A" sort="Saint Cyr, Jean A" uniqKey="Saint Cyr J" first="Jean A" last="Saint-Cyr">Jean A. Saint-Cyr</name></author><author><name sortKey="Wilson, Alan A" sort="Wilson, Alan A" uniqKey="Wilson A" first="Alan A" last="Wilson">Alan A. Wilson</name></author><author><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J" last="Kish">Stephen J. Kish</name></author></analytic><series><title level="j">The Journal of neuroscience : the official journal of the Society for Neuroscience</title><idno type="eISSN">1529-2401</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Analysis of Variance</term><term>Brain Mapping</term><term>Central Nervous System Stimulants (adverse effects)</term><term>Corpus Striatum (diagnostic imaging)</term><term>Corpus Striatum (pathology)</term><term>Female</term><term>Humans</term><term>Magnetic Resonance Imaging (methods)</term><term>Male</term><term>Methamphetamine (adverse effects)</term><term>Middle Aged</term><term>Neurologic Examination (methods)</term><term>Neuropsychological Tests</term><term>Parkinson Disease (diagnostic imaging)</term><term>Positron-Emission Tomography</term><term>Radiopharmaceuticals (metabolism)</term><term>Substance Withdrawal Syndrome (diagnostic imaging)</term><term>Substance Withdrawal Syndrome (metabolism)</term><term>Substance Withdrawal Syndrome (pathology)</term><term>Substance Withdrawal Syndrome (physiopathology)</term><term>Tetrabenazine (analogs & derivatives)</term><term>Tetrabenazine (metabolism)</term><term>Time Factors</term><term>Vesicular Monoamine Transport Proteins (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Central Nervous System Stimulants</term><term>Methamphetamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Tetrabenazine</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Corpus Striatum</term><term>Parkinson Disease</term><term>Substance Withdrawal Syndrome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Radiopharmaceuticals</term><term>Substance Withdrawal Syndrome</term><term>Tetrabenazine</term><term>Vesicular Monoamine Transport Proteins</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Magnetic Resonance Imaging</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Corpus Striatum</term><term>Substance Withdrawal Syndrome</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Substance Withdrawal Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Analysis of Variance</term><term>Brain Mapping</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuropsychological Tests</term><term>Positron-Emission Tomography</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Animal data indicate that methamphetamine can damage striatal dopamine terminals. Efforts to document dopamine neuron damage in living brain of methamphetamine users have focused on the binding of [(11)C]dihydrotetrabenazine (DTBZ), a vesicular monoamine transporter (VMAT2) positron emission tomography (PET) radioligand, as a stable dopamine neuron biomarker. Previous PET data report a slight decrease in striatal [(11)C]DTBZ binding in human methamphetamine users after prolonged (mean, 3 years) abstinence, suggesting that the reduction would likely be substantial in early abstinence. We measured striatal VMAT2 binding in 16 recently withdrawn (mean, 19 d; range, 1-90 d) methamphetamine users and in 14 healthy matched-control subjects during a PET scan with (+)[(11)C]DTBZ. Unexpectedly, striatal (+)[(11)C]DTBZ binding was increased in methamphetamine users relative to controls (+22%, caudate; +12%, putamen; +11%, ventral striatum). Increased (+)[(11)C]DTBZ binding in caudate was most marked in methamphetamine users abstinent for 1-3 d (+41%), relative to the 7-21 d (+15%) and >21 d (+9%) groups. Above-normal VMAT2 binding in some drug users suggests that any toxic effect of methamphetamine on dopamine neurons might be masked by an increased (+)[(11)C]DTBZ binding and that VMAT2 radioligand binding might not be, as is generally assumed, a "stable" index of dopamine neuron integrity in vivo. One potential explanation for increased (+)[(11)C]DTBZ binding is that VMAT2 binding is sensitive to changes in vesicular dopamine storage levels, presumably low in drug users. If correct, (+)[(11)C]DTBZ might be a useful imaging probe to correlate changes in brain dopamine stores and behavior in users of methamphetamine.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18815269</PMID><DateCreated><Year>2008</Year><Month>09</Month><Day>25</Day></DateCreated><DateCompleted><Year>2008</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>39</Issue><PubDate><Year>2008</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J. Neurosci.</ISOAbbreviation></Journal><ArticleTitle>Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?</ArticleTitle><Pagination><MedlinePgn>9850-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3008-08.2008</ELocationID><Abstract><AbstractText>Animal data indicate that methamphetamine can damage striatal dopamine terminals. Efforts to document dopamine neuron damage in living brain of methamphetamine users have focused on the binding of [(11)C]dihydrotetrabenazine (DTBZ), a vesicular monoamine transporter (VMAT2) positron emission tomography (PET) radioligand, as a stable dopamine neuron biomarker. Previous PET data report a slight decrease in striatal [(11)C]DTBZ binding in human methamphetamine users after prolonged (mean, 3 years) abstinence, suggesting that the reduction would likely be substantial in early abstinence. We measured striatal VMAT2 binding in 16 recently withdrawn (mean, 19 d; range, 1-90 d) methamphetamine users and in 14 healthy matched-control subjects during a PET scan with (+)[(11)C]DTBZ. Unexpectedly, striatal (+)[(11)C]DTBZ binding was increased in methamphetamine users relative to controls (+22%, caudate; +12%, putamen; +11%, ventral striatum). Increased (+)[(11)C]DTBZ binding in caudate was most marked in methamphetamine users abstinent for 1-3 d (+41%), relative to the 7-21 d (+15%) and >21 d (+9%) groups. Above-normal VMAT2 binding in some drug users suggests that any toxic effect of methamphetamine on dopamine neurons might be masked by an increased (+)[(11)C]DTBZ binding and that VMAT2 radioligand binding might not be, as is generally assumed, a "stable" index of dopamine neuron integrity in vivo. One potential explanation for increased (+)[(11)C]DTBZ binding is that VMAT2 binding is sensitive to changes in vesicular dopamine storage levels, presumably low in drug users. If correct, (+)[(11)C]DTBZ might be a useful imaging probe to correlate changes in brain dopamine stores and behavior in users of methamphetamine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boileau</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Human Neurochemical Pathology Laboratory, University of Toronto, Toronto, Ontario, Canada. isabelle_boileau@camh.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rusjan</LastName><ForeName>Pablo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Houle</LastName><ForeName>Sylvain</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wilkins</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Junchao</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Selby</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Guttman</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Saint-Cyr</LastName><ForeName>Jean A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Alan A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Kish</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000697">Central Nervous System Stimulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050493">Vesicular Monoamine Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>3466-75-9</RegistryNumber><NameOfSubstance UI="C032811">dihydrotetrabenazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>44RAL3456C</RegistryNumber><NameOfSubstance UI="D008694">Methamphetamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>Z9O08YRN8O</RegistryNumber><NameOfSubstance UI="D013747">Tetrabenazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000697" MajorTopicYN="N">Central Nervous System Stimulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008694" MajorTopicYN="N">Methamphetamine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013375" MajorTopicYN="N">Substance Withdrawal Syndrome</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013747" MajorTopicYN="N">Tetrabenazine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050493" MajorTopicYN="N">Vesicular Monoamine Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>11</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18815269</ArticleId><ArticleId IdType="pii">28/39/9850</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3008-08.2008</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><noCountry><name sortKey="Guttman, Mark" sort="Guttman, Mark" uniqKey="Guttman M" first="Mark" last="Guttman">Mark Guttman</name><name sortKey="Houle, Sylvain" sort="Houle, Sylvain" uniqKey="Houle S" first="Sylvain" last="Houle">Sylvain Houle</name><name sortKey="Kish, Stephen J" sort="Kish, Stephen J" uniqKey="Kish S" first="Stephen J" last="Kish">Stephen J. Kish</name><name sortKey="Rusjan, Pablo" sort="Rusjan, Pablo" uniqKey="Rusjan P" first="Pablo" last="Rusjan">Pablo Rusjan</name><name sortKey="Saint Cyr, Jean A" sort="Saint Cyr, Jean A" uniqKey="Saint Cyr J" first="Jean A" last="Saint-Cyr">Jean A. Saint-Cyr</name><name sortKey="Selby, Peter" sort="Selby, Peter" uniqKey="Selby P" first="Peter" last="Selby">Peter Selby</name><name sortKey="Tong, Junchao" sort="Tong, Junchao" uniqKey="Tong J" first="Junchao" last="Tong">Junchao Tong</name><name sortKey="Wilkins, Diana" sort="Wilkins, Diana" uniqKey="Wilkins D" first="Diana" last="Wilkins">Diana Wilkins</name><name sortKey="Wilson, Alan A" sort="Wilson, Alan A" uniqKey="Wilson A" first="Alan A" last="Wilson">Alan A. Wilson</name></noCountry><country name="Canada"><region name="Ontario"><name sortKey="Boileau, Isabelle" sort="Boileau, Isabelle" uniqKey="Boileau I" first="Isabelle" last="Boileau">Isabelle Boileau</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000F48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:18815269
|texte= Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:18815269" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |